Aurobindo Pharma USA Inc – FDA 483, May 13, 2024
The FDA inspected Aurobindo Pharma USA Inc."s corporate headquarters from May 13-15, 2024, uncovering critical non-compliance with the Drug Supply Chain Security Act (DSCSA). The primary issues observed included a systemic failure to implement robust procedures and systems for verifying product legitimacy and managing supply chain security. Specifically, the company"s written procedures were inadequate for identifying suspect products, conducting investigations with trading partners, validating transaction information, and ensuring timely notifications (within 24 hours) to the FDA regarding suspect, illegitimate, or high-risk products, as required by the DSCSA. Furthermore, Aurobindo Pharma lacked established systems to respond to notifications of illegitimate products from the FDA or trading partners, or to handle requests for product identifier verification. A significant violation involved the company"s failure to notify the FDA within 24 hours of a cargo theft on May 31, 2023, involving prescription drug products, which are considered illegitimate under the DSCSA. To achieve compliance, Aurobindo Pharma is required to develop and implement comprehensive systems and update their standard operating procedures to align with federal drug supply chain security regulations, ensuring proper investigation, notification, and response protocols.
ID · 23d87088-0c57-415a-b47d-edecbaeb8f2b
Comes with the profile
KRA (KeyPedia Risk Analysis)
How likely the FDA is to take enforcement action in the next 12 months.
Example18-month trend
Form 483 · May 13, 2024
What you get
A document
One file.
- One FDA document, such as a Form 483
- Yours for life in your Library
- Each has its own price
The profile
All the documents, plus intelligence about the company.
- Every Aurobindo Pharma USA Inc document on file
- The KRA score, which a single document does not include
- Observations and inspection history
Access
This, for every company on KeyPedia.
- Combine profiles in one search
- Search across any modality: products, industry types, drugs, devices and recalls
- Track everything as it changes
- Other agencies too, such as EMA, Health Canada and UK MHRA